BRAF Inhibitor-Driven Tumor Proliferation in a KRAS-Mutated Colon Carcinoma Is Not Overcome by MEK1/2 Inhibition

被引：43
|
作者：
Andrews, Miles C. [1 ]
Behren, Andreas [2 ]
Chionh, Fiona [2 ]
Mariadason, John [2 ]
Vella, Laura J. [2 ]
Do, Hongdo [3 ]
Dobrovic, Alexander [3 ]
Tebbutt, Niall [1 ]
Cebon, Jonathan [1 ]
机构：
[1] Austin Hlth, Joint Ludwig Austin Oncol Unit, Melbourne, Vic, Australia
[2] Ludwig Inst Canc Res, Austin Branch, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 35期
关键词：
SQUAMOUS-CELL CARCINOMAS; ADVANCED MELANOMA; RAF INHIBITORS; MUTATIONS; SURVIVAL; V600E;
D O I：
10.1200/JCO.2013.50.4118
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：E448 / E451
页数：4
相关论文
共 50 条
  • [31] EFFECTS OF TORC1/2 INHIBITOR MLN0128 ALONE AND IN COMBINATION WITH MEK INHIBITION IN BRAF MUTATED GLIOMA MODELS IN VITRO AND IN VIVO
    Liu, Kevin X.
    Mueller, Sabine
    Dik, Rogier
    Yang, Xiaodong
    DuBois, Steven
    Waanders, Angela J.
    Resnick, Adam C.
    Weiss, William A.
    Haas-Kogan, Daphne
    NEURO-ONCOLOGY, 2017, 19 : 85 - 86
  • [32] Azelnidipine inhibits esophageal squamous cell carcinoma proliferation in vivo and in vitro by targeting MEK1/2
    Zhao, Lili
    Zhang, Yuhan
    Li, Ang
    Lu, Xuebo
    Li, Mingzhu
    Yuan, Qiang
    Yang, Ning
    Zhao, Xiaokun
    Li, Xin
    Jiang, Yanan
    Liu, Kangdong
    MOLECULAR THERAPY ONCOLYTICS, 2022, 27 : 61 - 72
  • [33] Differential effects of Mek1 and Mek2 inhibition on cellular proliferation of malignant and non-malignant human breast cells
    Jeffress, Mara
    Beliveau, Alain
    Campeau, Eric
    Yaswen, Paul
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3474S - 3474S
  • [34] SMK-17, a MEK1/2-specific inhibitor, selectively induces apoptosis in β-catenin-mutated tumors
    Masaki Kiga
    Ayako Nakayama
    Yuki Shikata
    Yukiko Sasazawa
    Ryo Murakami
    Toshiyuki Nakanishi
    Etsu Tashiro
    Masaya Imoto
    Scientific Reports, 5
  • [35] Preclinical therapeutic synergy of MEK1/2 and IGF1R inhibition in RAS-driven rhabdomyosarcoma
    Yohe, M.
    Wan, X.
    Roth, J.
    Isanogle, K.
    Robinson, C.
    Liu, X.
    Chen, J.
    Hall, M.
    Difilippantonio, S.
    Khan, J.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S48 - S48
  • [36] SMK-17, a MEK1/2-specific inhibitor, selectively induces apoptosis in β-catenin-mutated tumors
    Kiga, Masaki
    Nakayama, Ayako
    Shikata, Yuki
    Sasazawa, Yukiko
    Murakami, Ryo
    Nakanishi, Toshiyuki
    Tashiro, Etsu
    Imoto, Masaya
    SCIENTIFIC REPORTS, 2015, 5
  • [37] Targeted inhibition of the MEK-ERK signaling cascade by the selective MEK1/2 inhibitor AZD6244 (ARRAY-142886) for the treatment of hepatocellular carcinoma.
    Tran, Evelyne
    Soo, Khee Chee
    Chow, Pierce
    Huynh, Hung
    CANCER RESEARCH, 2006, 66 (08)
  • [38] E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases
    Babiker, Hani M.
    Byron, Sara A.
    Hendricks, William P. D.
    Elmquist, William F.
    Gampa, Gautham
    Vondrak, Jessica
    Aldrich, Jessica
    Cuyugan, Lori
    Adkins, Jonathan
    De Luca, Valerie
    Tibes, Raoul
    Borad, Mitesh J.
    Marceau, Katie
    Myers, Thomas J.
    Paradiso, Linda J.
    Liang, Winnie S.
    Korn, Ronald L.
    Cridebring, Derek
    Von Hoff, Daniel D.
    Carpten, John D.
    Craig, David W.
    Trent, Jeffrey M.
    Gordon, Michael S.
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 636 - 645
  • [39] E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases
    Hani M. Babiker
    Sara A. Byron
    William P. D. Hendricks
    William F. Elmquist
    Gautham Gampa
    Jessica Vondrak
    Jessica Aldrich
    Lori Cuyugan
    Jonathan Adkins
    Valerie De Luca
    Raoul Tibes
    Mitesh J. Borad
    Katie Marceau
    Thomas J. Myers
    Linda J. Paradiso
    Winnie S. Liang
    Ronald L. Korn
    Derek Cridebring
    Daniel D. Von Hoff
    John D. Carpten
    David W. Craig
    Jeffrey M. Trent
    Michael S. Gordon
    Investigational New Drugs, 2019, 37 : 636 - 645
  • [40] Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma (vol 7, 46244, 2017)
    Song, Chengli
    Wang, Lina
    Xu, Qiang
    Wang, Kai
    Xie, Dan
    Yu, Zhe
    Jiang, Kui
    Liao, Lujian
    Yates, John R.
    Lee, Jiing-Dwan
    Yang, Qingkai
    SCIENTIFIC REPORTS, 2017, 7
12345